Santos da Silva Jorge's Form 4 filing
MoonLake Immunotherapeutics (MLTX) · filed Feb 29, 2024
- Accession no.
- 0001213900-24-018675
- Filed
- Feb 29, 2024
- Trade date
- Feb 27-29, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions. Open-market sales total $6.80M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Santos da Silva JorgeCIK 0001920509 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2024 | Class A ordinary shares, par value $0.0001 per share | SSaleDisposed | −62,810 | $55.00 | −$3,454,550 | 3,043,619 | Direct | |
| Feb 28, 2024 | Class A ordinary shares, par value $0.0001 per share | SSaleDisposed | −56,065 | $55.00 | −$3,083,575 | 2,987,554 | Direct | |
| Feb 29, 2024 | Class A ordinary shares, par value $0.0001 per share | SSaleDisposed | −4,740 | $55.89F2 | −$264,918.6 | 2,982,814 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.50 to $57.55. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.